News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Valeant Pharmaceuticals International (VRX) Reports 2013 First Quarter Financial Results


5/2/2013 7:01:58 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LAVAL, Quebec, May 2, 2013 /PRNewswire/ --

• 2013 First Quarter Total Revenue $1.068 billion; an increase of 25% over the prior year

• 2013 First Quarter Product Sales $1.039 billion; an increase of 38% over the prior year

? Organic growth (same store sales) was 6%, excluding the impact from generics, primarily BenzaClin and Cesamet

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES